Rapport Therapeutics, Inc. RAPP
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 99.11% | 183.04% | -- | -- | -- |
| Gross Profit | -51.78% | -80.85% | -- | -- | -- |
| SG&A Expenses | 37.65% | 36.73% | 37.03% | 51.02% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 70.51% | 52.80% | 50.62% | 48.14% | -- |
| Operating Income | -50.85% | -31.31% | -50.62% | -48.14% | -- |
| Income Before Tax | -55.31% | -34.60% | -42.37% | -36.00% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -55.31% | -34.60% | -42.37% | -35.99% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.31% | -34.60% | -42.37% | -35.99% | -- |
| EBIT | -50.85% | -31.31% | -50.62% | -48.14% | -- |
| EBITDA | -51.36% | -31.55% | -50.92% | -48.04% | -- |
| EPS Basic | -21.21% | 24.64% | 79.31% | 87.24% | -- |
| Normalized Basic EPS | -21.20% | 24.64% | 72.01% | 84.58% | -- |
| EPS Diluted | -21.21% | 24.64% | 79.31% | 87.24% | -- |
| Normalized Diluted EPS | -21.20% | 24.64% | 72.01% | 84.58% | -- |
| Average Basic Shares Outstanding | 27.72% | 44.65% | 88.31% | 191.75% | -- |
| Average Diluted Shares Outstanding | 27.72% | 44.65% | 88.31% | 191.75% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |